Hikma Pharmaceuticals USA Inc. recalls Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25…
- Recall date
- December 17, 2019
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- D-0658-2020
- FDA classification
- Class II
- Brand / firm
- Hikma Pharmaceuticals USA Inc.
- Sold / distributed
- Nationwide within the United States
Why it was recalled
Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (NDC 0641-6043-25), For IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.
Get recall alerts
Free email alert whenever Hikma Pharmaceuticals USA Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Hikma Pharmaceuticals USA Inc.